Trimanos
is a specialist service for enhancing the management of the clinical
research process, whether in the development of new drugs and therapies,
or in the oversight and evaluation of established ones.
Trimanos believes a new approach is needed to the conduct of clinical research. This will require changes in the operational use of information and communications technologies, but even more a new social and ethical framework within which to work. Trimanos has been designed with both objectives in mind.
The Trimanos information technology platform has its origins in research and development funded by the European Commission from 1987 - 1992. This platform has been in continuous development since, and systems were successfully used in both Sponsor and CRO settings during the 1990s.
As the nature of clinical research came under increasing scrutiny, Trimanos was then redesigned to encompass the needs of all stakeholders, and in particular whole new components have been added to assist subjects and sites. The full offering now includes:
Knowledge management
Training and reference
Data capture and retrieval
Work flow, documentation and SOPs
Regulatory compliance and GCP.
Independence and Peer Review
To make safe, effective, commercially sustainable progress, all stakeholders have to be engaged on equal terms, on the basis of trust and transparency. This is why Trimanos itself is independently financed. There are no hidden agendas. All Trimanos program content is subject to peer review.
Leadership
The leadership of Trimanos has played a part in advancing the quality of clinical research by:
- Co founding and developing the Association of Clinical Research Professionals
- Introducing certification for clinical research staff, notably investigators
- Promoting GCP compliance through innovative training programs in best practices
- Conducting trials at leading sites continuously for over thirty years
- Working with sponsors and CROs on innovative systems for trial management, such as on-line training and remote data entry
- Working with regulators and leading consulting firms to define new approaches to safety and ethics, especially in protecting human subjects
- Providing multimedia information and training systems on key diseases for healthcare professionals and patients, in partnership with leading pharmaceutical companies
- Collaborating with international or national bodies such as WHO and NIH in innovative approaches to disease prevention and control